Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet for High Blood Pressure
This trial seeks to find a way to lower the risk of cardiovascular events for obese individuals by specifically targeting the natriuretic peptides to control blood pressure.
- High Blood Pressure
- Renin-Angiotensin Aldosterone System
- Natriuretic Peptides
- Cardiovascular Disease
- Nocturnal Hypertension
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are we still looking for more participants for this experiment?
"The trial is still recruiting patients, according to the clinicaltrials.gov listing. The posting went up on February 18th, 2022 and was edited as recently as October 14th of the same year."
Are there any other ongoing research projects studying Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet?
"There are currently 39 ongoing clinical trials studying the efficacy of Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet. Of those, 8 are large Phase 3 trials. The majority of these studies are taking place in Montreal, Quebec; however, there are a total of 812 research sites worldwide."
What is the therapeutic target for Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet?
"The ventricular dysfunction, left can often be treated by taking Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet. This medication is also able to help patients that are struggling with essential hypertension or have a history of cardiovascular events."
How many people are being enrolled in this clinical trial?
"You are correct, the trial is still recruiting patients. The information on clinicaltrials.gov shows that the trial was posted on 2/18/2022 and updated on 10/14/2022. Currently, they are looking to enroll 160 patients from 1 location."